Moreover, a cross-reactive human monoclonal Notch2 and Notch3 antagonist, OMP-59R5 (Tarextumab), is effective in reducing cancer cell proliferation and the growth of breast, lung, ovarian, and pancreatic cancers [113]. Here, NOTCH3 is linked to familial pancreatic carcinoma.